Trials / Completed
CompletedNCT06119347
Acute Kidney Injury in Cancer Patients Receiving Anti-Vascular Endothelial Growth Factor Monoclonal Antibody vs Immune Checkpoint Inhibitors
Acute Kidney Injury in Cancer Patients Receiving Anti-Vascular Endothelial Growth Factor Monoclonal Antibody vs Immune Checkpoint Inhibitors: a Retrospective Real-world Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,581 (actual)
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University · Academic / Other
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this a retrospective real-world study is to compare the AKI events in cancer patients receiving anti-vascular endothelial growth factor monoclonal antibody (AntiVEGF) vs immune checkpoint inhibitors (ICIs). The main question it aims to answer is whether the choice between AntiVEGF and ICIs affects the risks of acute kidney injury in cancer patients. Cancer patients receiving AntiVEGF will be compared to those treated with ICIs to see if the AKI incidence is higher in patients receiving ICIs.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AntiVEGF | anti-vascular endothelial growth factor monoclonal antibody drug includes bevacizumab; |
| DRUG | ICIs | immune checkpoint inhibitors include Pembrolizumab, Sintilimab, toripalimab, Camrelizumab, Tislelizumab. |
Timeline
- Start date
- 2020-01-01
- Primary completion
- 2023-06-30
- Completion
- 2023-10-10
- First posted
- 2023-11-07
- Last updated
- 2023-11-08
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06119347. Inclusion in this directory is not an endorsement.